Greece · Delayed Price · Currency is EUR Evrofarma Statistics
Total Valuation
Evrofarma has a market cap or net worth of EUR 50.83 million. The enterprise value is 63.21 million.
| Market Cap | 50.83M |
| Enterprise Value | 63.21M |
Important Dates
The last earnings date was Friday, September 25, 2026.
| Earnings Date | Sep 25, 2026 |
| Ex-Dividend Date | Sep 15, 2026 |
Share Statistics
Evrofarma has 13.66 million shares outstanding. The number of shares has decreased by -0.02% in one year.
| Current Share Class | 13.66M |
| Shares Outstanding | 13.66M |
| Shares Change (YoY) | -0.02% |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | 75.08% |
| Owned by Institutions (%) | n/a |
| Float | 3.40M |
Valuation Ratios
The trailing PE ratio is 11.76.
| PE Ratio | 11.76 |
| Forward PE | n/a |
| PS Ratio | 0.99 |
| PB Ratio | 2.19 |
| P/TBV Ratio | 2.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 6.73 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 14.62 |
| EV / Sales | 1.23 |
| EV / EBITDA | 8.33 |
| EV / EBIT | 12.26 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.78, with a Debt / Equity ratio of 0.77.
| Current Ratio | 1.78 |
| Quick Ratio | 1.14 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | 2.37 |
| Debt / FCF | n/a |
| Interest Coverage | 8.72 |
Financial Efficiency
Return on equity (ROE) is 20.17% and return on invested capital (ROIC) is 11.17%.
| Return on Equity (ROE) | 20.17% |
| Return on Assets (ROA) | 5.37% |
| Return on Invested Capital (ROIC) | 11.17% |
| Return on Capital Employed (ROCE) | 10.63% |
| Weighted Average Cost of Capital (WACC) | 6.65% |
| Revenue Per Employee | 257,940 |
| Profits Per Employee | 21,615 |
| Employee Count | 200 |
| Asset Turnover | 0.86 |
| Inventory Turnover | 4.78 |
Taxes
In the past 12 months, Evrofarma has paid 1.28 million in taxes.
| Income Tax | 1.28M |
| Effective Tax Rate | 22.87% |
Stock Price Statistics
The stock price has increased by +40.91% in the last 52 weeks. The beta is 0.70, so Evrofarma's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | +40.91% |
| 50-Day Moving Average | 3.95 |
| 200-Day Moving Average | 3.79 |
| Relative Strength Index (RSI) | 43.55 |
| Average Volume (20 Days) | 3,765 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Evrofarma had revenue of EUR 51.59 million and earned 4.32 million in profits. Earnings per share was 0.32.
| Revenue | 51.59M |
| Gross Profit | 11.34M |
| Operating Income | 5.16M |
| Pretax Income | 5.61M |
| Net Income | 4.32M |
| EBITDA | 7.52M |
| EBIT | 5.16M |
| Earnings Per Share (EPS) | 0.32 |
Balance Sheet
The company has 5.58 million in cash and 17.96 million in debt, with a net cash position of -12.38 million or -0.91 per share.
| Cash & Cash Equivalents | 5.58M |
| Total Debt | 17.96M |
| Net Cash | -12.38M |
| Net Cash Per Share | -0.91 |
| Equity (Book Value) | 23.24M |
| Book Value Per Share | 1.70 |
| Working Capital | 10.88M |
Cash Flow
In the last 12 months, operating cash flow was 7.55 million and capital expenditures -7.90 million, giving a free cash flow of -348,000.
| Operating Cash Flow | 7.55M |
| Capital Expenditures | -7.90M |
| Depreciation & Amortization | 2.37M |
| Net Borrowing | -766,000 |
| Free Cash Flow | -348,000 |
| FCF Per Share | -0.03 |
Margins
Gross margin is 21.99%, with operating and profit margins of 9.99% and 8.38%.
| Gross Margin | 21.99% |
| Operating Margin | 9.99% |
| Pretax Margin | 10.86% |
| Profit Margin | 8.38% |
| EBITDA Margin | 14.58% |
| EBIT Margin | 9.99% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.06, which amounts to a dividend yield of 1.61%.
| Dividend Per Share | 0.06 |
| Dividend Yield | 1.61% |
| Dividend Growth (YoY) | 20.26% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 15.73% |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.02% |
| Shareholder Yield | 1.64% |
| Earnings Yield | 8.50% |
| FCF Yield | -0.68% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 26, 2001. It was a forward split with a ratio of 2.
| Last Split Date | Jul 26, 2001 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Evrofarma has an Altman Z-Score of 2.34 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.34 |
| Piotroski F-Score | 6 |